about
Role and New Insights of Pirfenidone in Fibrotic DiseasesVascular and plaque imaging with ultrasmall superparamagnetic particles of iron oxideEfficacy and safety of pirfenidone for idiopathic pulmonary fibrosisTGF-β/Smad signaling in renal fibrosisInhibitors/antagonists of TGF-β system in kidney fibrosisPresent and future in the treatment of diabetic kidney diseaseN-acetyl-seryl-aspartyl-lysyl-proline: a valuable endogenous anti-fibrotic peptide for combating kidney fibrosis in diabetesImprovements in the Management of Diabetic NephropathyRole of bone morphogenetic protein-7 in renal fibrosisDiabetic Kidney Disease: Pathophysiology and Therapeutic TargetsImproved mitochondrial function underlies the protective effect of pirfenidone against tubulointerstitial fibrosis in 5/6 nephrectomized ratsMefunidone attenuates tubulointerstitial fibrosis in a rat model of unilateral ureteral obstructionTherapeutic Modalities in Diabetic Nephropathy: Future Approaches.Fibrosis-related biomarkers and risk of total and cause-specific mortality: the cardiovascular health studyFibrosis-related biomarkers and incident cardiovascular disease in older adults: the cardiovascular health study.Fluorofenidone offers improved renoprotection at early interventions during the course of diabetic nephropathy in db/db mice via multiple pathwaysEmerging drugs for chronic kidney disease.Treatment with pirfenidone for two years decreases fibrosis, cytokine levels and enhances CB2 gene expression in patients with chronic hepatitis C.Urinary microRNA profiling in the nephropathy of type 1 diabetes.Risk of ESRD and all cause mortality in type 2 diabetes according to circulating levels of FGF-23 and TNFR1.Renal function can improve at any stage of chronic kidney disease.Therapeutic targets for treating fibrotic kidney diseasesEpigenetics in diabetic kidney disease.Signaling mechanisms in the regulation of renal matrix metabolism in diabetes.Fibrosis-related biomarkers and large and small vessel disease: the Cardiovascular Health Study.Antioxidants in kidney diseases: the impact of bardoxolone methyl.Twenty years after ACEIs and ARBs: emerging treatment strategies for diabetic nephropathy.Protective effects of GLP-1 on glomerular endothelium and its inhibition by PKCβ activation in diabetesDiabetic nephropathy: What does the future hold?Comprehensive approach to diabetic nephropathy.Diabetic nephropathy: the role of inflammation in fibroblast activation and kidney fibrosis.Cellular mechanisms of tissue fibrosis. 3. Novel mechanisms of kidney fibrosis.TGF-β signaling in the kidney: profibrotic and protective effectsDiscoidin domain receptor-1 and periostin: new players in chronic kidney diseaseMetabolomics reveals signature of mitochondrial dysfunction in diabetic kidney diseasemiR-34c attenuates epithelial-mesenchymal transition and kidney fibrosis with ureteral obstruction.What are new avenues for renal protection, in addition to RAAS inhibition?Cellular and molecular mechanisms of diabetic glomerulopathy.Pathophysiology of the aging kidney and therapeutic interventions.Resolution of inflammation: therapeutic potential of pro-resolving lipids in type 2 diabetes mellitus and associated renal complications.
P2860
Q26774154-61FD65CD-A87B-4DA8-9061-315EF6DDBFB3Q26783581-FC1C8865-261B-44F0-AFE0-8B565F1652EAQ26849378-D84A349B-716C-415C-827B-E070146FFD2FQ26851198-AD1C71DF-4D13-4056-A9BE-233CDEEEB588Q26852400-286E8709-F61D-4AD4-BC38-03F97BFBD69EQ26864133-DD8C8A8E-7790-444C-8E98-E800A15D0EFAQ27008887-1E786E67-E359-4D59-8689-CE42BC40390AQ28080717-A519D23A-B664-47C5-9BA9-2A159BD73736Q28080865-C0210256-E5D8-4067-B263-E464901C5C7CQ28086840-097C78F8-9153-4F63-8434-8FBE5EB07583Q28536610-E384F43E-F43D-4273-89FA-B87B8C3F5FB0Q28547858-B20923C4-95E1-4871-9212-806DCEADB81FQ30423005-B71F2B5C-58AA-400C-8AE8-C0FF088F4E4AQ33676034-A54C22FC-786D-4B0B-AC3F-5FF149A475DBQ34076151-997B0746-7B81-4A48-98B0-C9D6EA036FAFQ34408514-F6F0D3CA-7522-4510-B75F-DD2FEBCF9A30Q34420383-ED270C70-E29E-4543-9F18-47363E05CC95Q34537906-99B19340-10DD-4E7B-A4CD-7F3B08F417C2Q34566051-D9C0CC45-9D48-4C1A-9D23-2ED19E77C194Q34634066-19156663-58A4-4958-9175-60EBE4A34040Q35069799-AAA5C5D0-C1DC-4186-8F5A-5E057135EACDQ35079607-83BEDE66-3440-4341-9497-B59529948CD3Q35647853-9C4720A1-ADC3-442C-80CC-32C41617CF2EQ35791976-064B7858-77B1-4459-99F4-66426BCC14B8Q35897206-ACCE6599-9BDC-4D49-9297-6E6058FF72DCQ36026304-7F7CE170-E2D1-4E3F-8362-CA9EA89710CBQ36297539-D2545BC4-94E2-4B3A-92B6-6AADB6397257Q36339470-111EB60A-7961-46FA-AEBF-8D302C5871FEQ36441616-396DE116-93A7-4595-82CF-B9EF2CDD97A1Q36466019-3C4F0287-8FB2-43F2-AF1F-DDDCDC0123E6Q36589609-A1207EC7-E8BC-4046-9338-3F31F1F6DCA2Q36763871-8D786E95-BF12-4866-9F0B-3DA43B1CAB79Q36775661-53724500-3D4E-4D2D-B5C2-77BBEB60DD98Q36801573-98313EAA-0CBA-4925-9390-D56DFC797EABQ37260216-BA4292D0-F165-4FB6-946E-0F4530AD8CC0Q37681848-D1CE4BB2-5EC7-441F-AA52-3721C384E2C1Q37980677-E04C58B2-A112-409B-98BB-BE2EBD519743Q38010045-774F8A11-8084-4BE1-87C2-9F8B577D7669Q38053074-5F19A067-788C-4F51-B3EA-4B49C27877A4Q38054089-D95D1DFA-1D4D-4582-82F2-6DE1B6209505
P2860
description
2011 nî lūn-bûn
@nan
2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Pirfenidone for diabetic nephropathy.
@ast
Pirfenidone for diabetic nephropathy.
@en
type
label
Pirfenidone for diabetic nephropathy.
@ast
Pirfenidone for diabetic nephropathy.
@en
prefLabel
Pirfenidone for diabetic nephropathy.
@ast
Pirfenidone for diabetic nephropathy.
@en
P2093
P2860
P50
P356
P1476
Pirfenidone for diabetic nephropathy.
@en
P2093
Barbara Francos
Bonita Falkner
Fernando C Fervenza
Kumar Sharma
Michael Donohue
Monique Cho
Ronghui Xu
Satish Ramachandrarao
Shoba Sharma
Stephen R Dunn
P2860
P304
P356
10.1681/ASN.2010101049
P577
2011-04-21T00:00:00Z